agreements
Nestlé abandons $2 billion peanut allergy drug Palforzia after disappointing sales and safety issues
Anika Sharma
Nestlé has completed the sale of its peanut allergy drug, Palforzia, to the U.S.-based allergy specialist Stallergenes Greer for an ...
